570 related articles for article (PubMed ID: 24782185)
41. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study.
Askling J; Klareskog L; Blomqvist P; Fored M; Feltelius N
Ann Rheum Dis; 2006 Sep; 65(9):1184-7. PubMed ID: 16414970
[TBL] [Abstract][Full Text] [Related]
42. Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy.
Genest G; Spitzer KA; Laskin CA
J Rheumatol; 2018 Aug; 45(8):1109-1115. PubMed ID: 29961692
[TBL] [Abstract][Full Text] [Related]
43. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
Kim Y; Park S; Kim HS
Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
[TBL] [Abstract][Full Text] [Related]
44. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
45. Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication.
Dalén J; Svedbom A; Hernlund E; Olofsson T; Black CM
Adv Ther; 2023 Oct; 40(10):4657-4674. PubMed ID: 37599341
[TBL] [Abstract][Full Text] [Related]
46. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
[TBL] [Abstract][Full Text] [Related]
47. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
48. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants.
Eworuke E; Panucci G; Goulding M; Neuner R; Toh S
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):296-304. PubMed ID: 30430682
[TBL] [Abstract][Full Text] [Related]
49. The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.
Fong W; Holroyd C; Davidson B; Armstrong R; Harvey N; Dennison E; Cooper C; Edwards CJ
Rheumatology (Oxford); 2016 Oct; 55(10):1837-42. PubMed ID: 27354684
[TBL] [Abstract][Full Text] [Related]
50. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Zhou Y; Goldstein N; Braun J
J Rheumatol; 2016 Dec; 43(12):2120-2130. PubMed ID: 27803138
[TBL] [Abstract][Full Text] [Related]
51. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
[TBL] [Abstract][Full Text] [Related]
52. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
[TBL] [Abstract][Full Text] [Related]
53. Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study.
Cordtz RL; Askling J; Delcoigne B; Smedby KE; Baecklund E; Ballegaard C; Isomäki P; Aaltonen K; Gudbjornsson B; Love TJ; Provan SA; Michelsen B; Sexton J; Dreyer L; Hellgren K
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36564101
[TBL] [Abstract][Full Text] [Related]
54. Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.
Mease PJ; Lesperance T; Liu M; Collier DH; Mason M; Deveikis S; Accortt NA
J Rheumatol; 2017 Feb; 44(2):184-192. PubMed ID: 28089969
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
[TBL] [Abstract][Full Text] [Related]
56. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
[TBL] [Abstract][Full Text] [Related]
57. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink.
Edson-Heredia E; Zhu B; Lefevre C; Wang M; Barrett A; Bushe CJ; Cox A; Wu JJ; Maeda-Chubachi T
J Eur Acad Dermatol Venereol; 2015 May; 29(5):955-63. PubMed ID: 25352213
[TBL] [Abstract][Full Text] [Related]
58. Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations.
Accortt NA; Chung JB; Bonafede M; Limone BL; Mannino DM
Int J Chron Obstruct Pulmon Dis; 2017; 12():2085-2094. PubMed ID: 28790811
[TBL] [Abstract][Full Text] [Related]
59. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.
Dreyer L; Magyari M; Laursen B; Cordtz R; Sellebjerg F; Locht H
Ann Rheum Dis; 2016 Apr; 75(4):785-6. PubMed ID: 26698850
[No Abstract] [Full Text] [Related]
60. Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
Christensen IE; Lillegraven S; Mielnik P; Bakland G; Loli L; Sexton J; Uhlig T; Kvien TK; Provan SA
Ann Rheum Dis; 2022 Mar; 81(3):398-401. PubMed ID: 34625404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]